Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 28 May 1999:
Vol. 284. no. 5419, pp. 1471 - 1472
DOI: 10.1126/science.284.5419.1471
Prev | Table of Contents | Next

Policy Forum

GENETIC ENGINEERING:
A Rational Approach to Labeling Biotech-Derived Foods

Henry I. Miller

The FDA's risk-based approach to food labeling is consistent with the broad scientific consensus that the risks associated with recombinant organisms, and foods derived from them, are fundamentally the same as for other products. Dozens of new plant varieties modified with traditional genetic techniques (such as hybridization and mutagenesis) enter the marketplace every year without premarket regulatory review or special labeling; therefore, no consultation with the FDA, premarket review, or labeling is required unless the characteristics of the biotech food explicitly raise certain specified safety issues.

The author is at the Hoover Institution, Stanford University, Stanford, CA 94305, USA, and is an Adjunct Scholar, Competitive Enterprise Institute, Washington, DC 20036, USA. E-mail: miller{at}hoover.stanford.edu

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Innovation and Trade with Endogenous Market Failure: The Case of Genetically Modified Products.
H. E. Lapan and G. Moschini (2004)
Am. J. Agr. Econ. 86, 634-648
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)